Post-Transcriptional Genetic Silencing ofBCL11Ato Treat Sickle Cell Disease
Author(s) -
Erica B. Esrick,
Leslie E. Lehmann,
Alessandra Biffi,
Maureen Achebe,
Christian Brendel,
Marioara F. Ciuculescu,
Heather Daley,
Brenda L. MacKin,
Emily A. Morris,
Amy Federico,
Daniela Abriss,
Kari Boardman,
Radia Khelladi,
Kit L. Shaw,
Hélène Negre,
Olivier Nègre,
Sarah Nikiforow,
Jerome Ritz,
SungYun Pai,
Wendy B. London,
Colleen Dansereau,
Matthew M. Heeney,
Myriam Armant,
John P. Manis,
David A. Williams
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2029392
Subject(s) - gene silencing , disease , cell , genetics , medicine , biology , gene
Sickle cell disease is characterized by hemolytic anemia, pain, and progressive organ damage. A high level of erythrocyte fetal hemoglobin (HbF) comprising α- and γ-globins may ameliorate these manifestations by mitigating sickle hemoglobin polymerization and erythrocyte sickling. BCL11A is a repressor of γ-globin expression and HbF production in adult erythrocytes. Its down-regulation is a promising therapeutic strategy for induction of HbF.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom